Trial Profile

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Mar 2025 According to an EyePoint Pharmaceuticals media release, end-of-trial results of this trial presented at Angiogenesis Exudation, and Degeneration 2025 in February.
05 Mar 2025 According to an EyePoint Pharmaceuticals media release, 12 month data at the Hawaiian Eye & Retina annual meeting in January.
04 Dec 2024 According to an EyePoint Pharmaceuticals media release, the data from the DAVIO 2 clinical trial supported the advancement of the wet AMD program and the initiation of the global Phase 3 clinical trials, LUGANO and LUCIA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com